Agents for treating human illnesses based on .beta.-catenin, and the production and use thereof
CA 2357015 A1 · Owner: Von Kries, Jens-Peter · Inventors: Von Kries, Jens-Peter; Birchmeier, Walter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
beta.-catenin is a central molecule of the Wnt signal path. Increasing .beta.catenin in the cell leads to the translocation in the cell nucleus and to the interaction with transcription factors of the LEF-1/TCF family. This can lead to colonic cancers and melenomas (oncogenic signal path). However .beta.-, catenin also interacts with the tumor-suppressor genes APC conductin and E-, cadherin which have a contrary effect on the cell (anti-oncogenic effect). The invention relates to peptides derived from LEF-1-/TCF-4-transcription factors and analogous molecules in the treatment of tumors especially for treating , colonic cancers and melanomas. These peptides and analogous molecules …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 22, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 22, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 22, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.